AD	

Award Number: DAMD17-01-1-0658

TITLE: The Role of AIB1 in Estrogen-dependent Breast Tumor Cell

Growth

PRINCIPAL INVESTIGATOR: Fern E. Murdoch, Ph.D.

CONTRACTING ORGANIZATION:

University of Wisconsin-Madison Madison, Wisconsin 53706-1490

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030109 064

# REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blan		3. REPORT TYPE AND D		
4. TITLE AND SUBTITLE	July 2002	Final (1 Jul 01		
			5. FUNDING NUMBERS	
The Role of AIB1 in Estrogen-dependent Breast Tumor Cell Growth			DAMD17-01-1-0658	
C AUTUODIO)				
6. AUTHOR(S) Fern E. Murdoch, Ph.D.				
rein E. Murdoch, P.				
			3. PERFORMING ORGANIZATION	
			REPORT NUMBER	
Madison, Wisconsin 53706-1490				
E Maile ( )				
E-Mail: femurdoch@facstaff.wisc.ed				
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(ES	S) 1	10. SPONSORING / MONITORING	
U.S. Army Medical Research and	Materiel Command		AGENCY REPORT NUMBER	
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				
, , , , , , , , , , , , , , , , , , , ,				
11. SUPPLEMENTARY NOTES				
THE GOLD COMENTANT NOTES				
40 DIOTRIDITION / ANIAM ADVICE				
12a. DISTRIBUTION / AVAILABILIT		limitad	12b. DISTRIBUTION CODE	
	Y STATEMENT lease; Distribution Un	limited	12b. DISTRIBUTION CODE	
		limited	12b. DISTRIBUTION CODE	
		limited	12b. DISTRIBUTION CODE	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo	lease; Distribution Uni			
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo  AIB1, a pl60 coactivato	lease; Distribution Uni	ceptor (ER) and in	creases estrogen-dependent	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo  AIB1, a p160 coactivate transcription. It is	rds)  or, binds to estrogen representation of the content of the c	eceptor (ER) and in	creases estrogen-dependent	
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is of genes required for esti	rds)  or, binds to estrogen respectively of the content of the con	eceptor (ER) and in primary breast tum	creases estrogen-dependent fors. We hypothesize that leir transcription. Our	
13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is a genes required for esta hypothesis predicts that	rds)  or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth until decreasing AIB1 shoul	eceptor (ER) and in primary breast tum Itilize AIB1 for th	creases estrogen-dependent fors. We hypothesize that eir transcription. Our edependent growth and	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts the transcription. Our exp	rds)  or, binds to estrogen recoverexpressed in 64% of cogen-dependent growth until decreasing AIB1 should be the control of the control of the country of t	eceptor (ER) and in primary breast tum Itilize AIB1 for th d inhibit estrogen design inhibitors t	creases estrogen-dependent fors. We hypothesize that eir transcription. Our edependent growth and o AIB1, introduce them	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts tha transcription. Our exp into MCF-7 cells, and a as end-points. We design	rds)  or, binds to estrogen represent the content of the content o	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first w	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts tha transcription. Our exp into MCF-7 cells, and a as end-points. We design	rds)  or, binds to estrogen respectively of the coverexpressed in 64% of cogen-dependent growth use the decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting amimo acids of the HIV Telegraphs.	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen design inhibitors to and progesterone tors. The first was a protein that ha	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for esta hypothesis predicts tha transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, and	rds)  or, binds to estrogen represent in 64% of cogen-dependent growth until decreasing AIB1 should be rimental goal was to disassay cell proliferation and two types of inhibiting amimo acids of the HIV Total the 19 amino acids from the second control of the 19 amino acids from the second control of the 19 amino acids from the 19 amino acid	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen design inhibitors to and progesterone tors. The first was a protein that has some the AIB1 LXXLL	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and AIB1, introduce them receptor (PgR) expression as a small polypeptide we been shown to transduce box 2 that has been shown	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, and to bind to ER. The ide	ords)  or, binds to estrogen represent in 64% of cogen-dependent growth use the decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting amimo acids of the HIV Total the 19 amino acids free was that this polypep	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has some the AIB1 LXXLL etide would compete	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and a AIB1, introduce them receptor (PgR) expression as a small polypeptide we been shown to transduce box 2 that has been shown with the endogenous.	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is genes required for esta hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, an to bind to ER. The ide full-length AIB1 for be	ords)  or, binds to estrogen represent in 64% of regen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting and the 19 amino acids from a was that this polypepending to ER and thereby	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a Table 1 Table	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and a AIB1, introduce them receptor (PgR) expression as a small polypeptide we been shown to transduce box 2 that has been shown with the endogenous, However, this	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, an to bind to ER. The ide full-length AIB1 for be polypeptide had no affe	ords)  or, binds to estrogen represent in 64% of regen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting and the 19 amino acids from the 19 amino acids from as that this polypepanding to ER and thereby ect on estrogen-dependent	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen design inhibitors to and progesterone tors. The first was a protein that has soon the AIB1 LXXLL of tide would competed disrupt function.	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We desic that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains	or, binds to estrogen recoverexpressed in 64% of regen-dependent growth us to decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from the 19 amin	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has soon the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in other interaction bother terms.	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo AIB1, a p160 coactivate transcription. It is o genes required for estr hypothesis predicts that transcription. Our exp into MCF-7 cells, and a as end-points. We desic that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for bi polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of	or, binds to estrogen recoverexpressed in 64% of regen-dependent growth us to decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from the 19 amin	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has soon the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in other interaction bother terms.	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wo  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We desic that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains	or, binds to estrogen recoverexpressed in 64% of regen-dependent growth us to decreasing AIB1 should be rimental goal was to decrease two types of inhibitions and the 19 amino acids from the 19 amin	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has soon the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in other interaction bother terms.	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent a inhibitor.	or, binds to estrogen represent in 64% of rogen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibitation acids of the HIV Total the 19 amino acids from a was that this polypepending to ER and thereby ect on estrogen-dependents and are stably transfall three nuclear receptors.	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has some the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in the tor interaction both in these cells are	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide we been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects e not yet known for this	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We desic that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor.	or, binds to estrogen represent in 64% of rogen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibitation acids of the HIV Total the 19 amino acids from a was that this polypepending to ER and thereby ect on estrogen-dependents and are stably transfall three nuclear receptors.	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has some the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in the tor interaction both in these cells are	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects e not yet known for this	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is a genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We desic that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent a inhibitor.	or, binds to estrogen represent in 64% of rogen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibitation acids of the HIV Total the 19 amino acids from a was that this polypepending to ER and thereby ect on estrogen-dependents and are stably transfall three nuclear receptors.	eceptor (ER) and in primary breast tum tilize AIB1 for the dinhibit estrogen lesign inhibitors to and progesterone tors. The first was a protein that has some the AIB1 LXXLL obtide would competed disrupt function. It growth or PgR expecting a second in the tor interaction both in these cells are	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects e not yet known for this	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor.  14. SUBJECT TERMS breast cancer, estroges	or, binds to estrogen recoverexpressed in 64% of rogen-dependent growth used decreasing AIB1 should be rimental goal was to decrease the first of th	eceptor (ER) and in primary breast tum stilize AIB1 for the dinhibit estrogen design inhibitors to and progesterone stors. The first was a protein that has some the AIB1 LXXLL stide would compete to disrupt function. It growth or PgR expecting a second in the second i	creases estrogen-dependent fors. We hypothesize that eir transcription. Our dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE-xes of the AIB1. Affects e not yet known for this	
Approved for Public Re  13. ABSTRACT (Maximum 200 Wa  AIB1, a p160 coactivate transcription. It is genes required for estr hypothesis predicts the transcription. Our exp into MCF-7 cells, and a as end-points. We design that contained the 11 a proteins into cells, ar to bind to ER. The ide full-length AIB1 for be polypeptide had no affe MCF-7 Tet-Off cell line promoter that contains on estrogen-dependent of inhibitor.  14. SUBJECT TERMS breast cancer, estroger	ords)  or, binds to estrogen represent in 64% of rogen-dependent growth until decreasing AIB1 should be rimental goal was to do assay cell proliferation and two types of inhibiting and the 19 amino acids from a was that this polypepending to ER and thereby est on estrogen-dependents and are stably transfall three nuclear receptors from the receptor, coactivators are receptor, coactivators.	eceptor (ER) and in primary breast tum stilize AIB1 for the dinhibit estrogen design inhibitors to and progesterone stors. The first was a protein that has some the AIB1 LXXLL of tide would compete to disrupt function. It growth or PgR expecting a second in the second	creases estrogen-dependent fors. We hypothesize that eir transcription. Our -dependent growth and o AIB1, introduce them receptor (PgR) expression as a small polypeptide ve been shown to transduce box 2 that has been shown with the endogenous, However, this pression. We have created hibitor under a TRE- xes of the AIB1. Affects e not yet known for this  15. NUMBER OF PAGES 6 16. PRICE CODE  ATION  20. LIMITATION OF ABSTRACT	

# **Table of Contents**

Cover1
SF 2982
Introduction4
Body4
Key Research Accomplishments5
Reportable Outcomes5
Conclusions6
References6
Appendicesnon

#### INTRODUCTION

AIB1, a p160 coactivator, binds to estrogen receptor (ER) and increases estrogendependent transcription. It is overexpressed in 64% of primary breast tumors. We hypothesize that genes required for estrogen-dependent growth utilize AIB1 for their transcription. Our hypothesis predicts that decreasing AIB1 should inhibit estrogendependent growth and transcription. Our experimental goal was to design inhibitors to AIB1, introduce them into MCF-7 cells, and assay cell proliferation and progesterone receptor (PgR) expression as end-points. We designed two types of inhibitors. The first was a small polypeptide that contained the 11 amino acids of the HIV TAT protein that have been shown to transduce proteins into cells, and the 19 amino acids from the AIB1 LXXLL box 2 that has been shown to bind to ER. The idea was that this polypeptide would compete with the endogenous, full-length AIB1 for binding to ER and thereby disrupt function. However, this polypeptide had no affect on estrogen-dependent growth or PgR expression. We have created MCF-7 Tet-Off cell lines and are stably transfecting a second inhibitor under a TRE-promoter that contains all three nuclear receptor interaction boxes of the AIB1. Affects on estrogen-dependent growth and transcription in these cells are not yet known for this inhibitor.

#### **BODY**

Our goal was to inhibit AIB1 function in MCF-7 cells to determine if this protein was required for estrogen-dependent cell growth or gene expression.

The first inhibitor we designed was to take advantage of the transduction sequence found in the HIV TAT protein. This small, 11 amino acid sequence, can transduce polypeptides into almost any cell type. Such an inhibitor would be quite versatile. We selected the box 2 LXXLL region of the AIB1 protein to add to the TAT sequence. We chose this fragment of AIB1, because it has the highest binding affinity for ER (1). The total peptide was

# YGRKKRRQRRRGQEKHRILHHKLLQNGNSPAE.

This peptide was chemically synthesized and added to the culture media of MCF-7 cells at a final concentration of up to 10 micromolar. Cells were treated with and without 1 nM estradiol and assayed for growth rate and progesterone receptor expression. Estradiol increased the doubling time of the cells from 350 hours to 67 hours in withdrawal media. Addition of the peptide had no affect on this doubling rate. The expression of progesterone receptor was assayed by whole cell uptake assays and western blot. Estradiol strongly induced expression of both isoforms of this protein from undetectable levels in withdrawal media over three days. Addition of the peptide had no affect on this doubling rate.

We verified the functionality of the peptide by assaying for the estradiol dissociation rate from estrogen receptor. Bound peptide was expected to substantially decrease the ligand dissociation rate since it stabilizes helix 12 in a conformation that covers the ligand binding pocket of ER (2). Our peptide had a dramatic effect on the dissociation of 3H-estradiol from the ER protein. The t(1/2) for estradiol on the ER was 34 minutes and was increased to 216 minutes in the presence of 10 micromolar peptide.

Using this assay we determined that the approximate binding affinity of our peptide to the ER in vitro was about 3 micromolar. Our failure to observe any effects of this peptide on estrogen-induced growth and transcription in our MCF-7 cells could be due to several problems; 1) failure to achieve a sufficiently high concentration, 2) degradation of the peptide in the cells, 3) failure of the peptide to localize to the nucleus. We chose a design for a second inhibitor that would address these potential problems.

The second AIB1 inhibitor we have constructed contains the fragment of the AIB1 cDNA from #1965-2489 (175 amino acids) that contains all three receptor interaction domains with LXXLL motifs, but none of the activation domains. The construct also contains the SV40 large T antigen nuclear localization signal, 2 HA antigen tags, and a Kozak sequence for efficient translation. Upon translation this construct will yield a 23Kd protein that will localize to the nucleus and efficiently bind the ER. We have constructed Tet-Off MCF-7 cell lines and are in the process of stably transfecting our construct into these cells under a TRE containing promoter. We chose this design to achieve the highest possible expression of the inhibitor without adding tetracycline to the media. Addition of tetracycline should inhibit expression of the inhibitor. Our future plans are to assay these stable cell lines for estrogen-dependent growth and gene expression in the presence and absence of tetracycline. We will be able to quantitate the expression of our inhibitor by Western blot for the HA tags and verify its nuclear localization by immunocytochemistry for the HA tags.

#### **KEY RESEARCH ACCOMPLISHMENTS**

- Characterization of TAT-LXXLL polypeptide as a potential inhibitor of ER-AIB1 interaction in vivo. Functioned to inhibit ligand dissociation in vitro, but did not affect ER function in MCF-7 cells.
- Derived and characterized MCF-7 cell lines stably expressing Tet-Off transcription factor. Cells lines were characterized for estrogen-induced growth and ERE-luciferase expression.
- Construction of construct for stable, repressible expression in MCF-7 cells of a second potential ER-AIB1 interaction inhibitor. Construct contains the receptor interaction domains of the AIB1 protein, 2 HA-tags, nuclear localization signal.

#### **REPORTABLE OUTCOMES**

- Development of Tet-off MCF-7 cell lines
- Construction of potential inhibitor of ER-AIB1 interactions

### **CONCLUSIONS**

The development of molecule that can disrupt ER-AIB1 interactions will provide a critical tool to dissect the estrogen-induced pathways that are dependent on this interaction. We have determined that he use of a TAT-peptide is not effective in our system, probably due to the limited concentrations we can achieve in the cell over time. We have turned our efforts to a stable expression system.

## **REFERENCES**

- 1. Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, and Katzenellenbogen JA (1999) Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. **Mol. Endocrinol. 13:**1912-23.
- 2. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, and Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-37.

#### **PERSONEL**

Carley Sauter Timothy Kruser Amy Stoddard Brittany Conrad